Logo do repositório
 
Publicação

Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder

2020Artigo científico Acesso restrito
Ver registo simples
dc.contributor.authorZastrozhin, Michael S.
dc.contributor.authorSkryabin, Valentin Y.
dc.contributor.authorTorrado, Marco
dc.contributor.authorPetrovna, Anastasiya
dc.contributor.authorSorokin, Alexander S.
dc.contributor.authorGrishina, Elena A.
dc.contributor.authorRyzhikova, Kristina A.
dc.contributor.authorBedina, Inessa A.
dc.contributor.authorBuzik, Oleg Z.
dc.contributor.authorChumakov, Egor M.
dc.contributor.authorSavchenko, Ludmila M.
dc.contributor.authorBrun, Evgeny A.
dc.contributor.authorSychev, Dmitry A.
dc.date.accessioned2020-01-23T15:16:21Z
dc.date.available2020-01-23T15:16:21Z
dc.date.issued2020
dc.description© 2020 Future Science Group.pt_PT
dc.description.abstractIntroduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A, rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 ± 7.84 years) received phenazepam in tablet form for 5 days. Genotyping was performed by real-time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1) 2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion: This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.pt_PT
dc.description.sponsorshipThis work was supported by the project titled “Fundamental research and exploratory research in priority areas of research” of the Russian Science Foundation and by the President’s Grant of state support for the young scientists (project MK-2460.2018.7).pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPharmacogenomics, 21(2), 111–123pt_PT
dc.identifier.doi10.2217/pgs-2019-0019pt_PT
dc.identifier.eissn1744-8042
dc.identifier.issn1462-2416
dc.identifier.urihttp://hdl.handle.net/10451/41355
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFuture Medicinept_PT
dc.relation.publisherversionhttps://www.futuremedicine.com/journal/pgspt_PT
dc.subjectAlcohol addictionpt_PT
dc.subjectAnxiety disorderspt_PT
dc.subjectBenzodiazepinespt_PT
dc.subjectBiotransformationpt_PT
dc.subjectBromodihydrochlorobenzodiazepinept_PT
dc.subjectCYP2C19pt_PT
dc.subjectPersonalized medicinept_PT
dc.subjectPhenazepampt_PT
dc.titleEffects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorderpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage123pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPage111pt_PT
oaire.citation.titlePharmacogenomicspt_PT
oaire.citation.volume21pt_PT
person.familyNameTorrado
person.givenNameMarco
person.identifier.ciencia-id8819-FC01-6618
person.identifier.orcid0000-0002-4091-745X
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationad82e95f-8586-4302-83c8-9028e9d969a6
relation.isAuthorOfPublication.latestForDiscoveryad82e95f-8586-4302-83c8-9028e9d969a6

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
CYP2C19.pdf
Tamanho:
719.56 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FM-ISAMB-Artigos em Revistas Internacionais